Wisevoter
Pennsylvania

Pennsylvania Warns of Rise in Opioid Withdrawal Cases

State health officials cite 7-OH overdose deaths and poison control data ahead of a planned federal rescheduling of the substance.

Updated on Nov. 7, 2026 in Substance Abuse

Flat vector editorial illustration of a tipped amber glass vial and loose capsules on a pale surface, evoking the risks of a controlled-substance warning.
The Pennsylvania Department of Health warned that federal plans to reschedule 7-OH and related kratom-derived substances as Schedule I drugs on November 13, 2026, could raise opioid withdrawal cases and overdose risk. AI Illustration. Upload story photo >

Live Poll

Should the federal government ban kratom-derived products like 7-OH?

The Pennsylvania Department of Health warned of an increase in opioid withdrawal patients tied to planned federal rescheduling of 7-OH, a kratom-derived substance with opioid-like effects. The Drug Enforcement Administration intends to reschedule 7-OH, MGM-15, MGM-16, and tianeptine as Schedule I controlled substances on November 13, 2026.

Why it matters

Officials said rescheduling could push people who use the substances toward street supplies or other illicit drugs, raising overdose risk. Groups using these products for pain management or who do not identify as having a substance use disorder may face heightened health risks and difficulty getting appropriate care.

Poison control records show 66 7-OH exposure cases and 284 kratom exposure cases in Pennsylvania from 2022 through June 30, 2026, of which 26 required ventilator support. Current overdose data does not separate natural kratom from synthetic 7-OH, leaving the specific contribution of each unclear.

The players

Pennsylvania Department of Health

The state agency responsible for public health in Pennsylvania, which issued the warning about rising opioid withdrawal cases.

Drug Enforcement Administration

The federal agency within the U.S. Department of Justice responsible for enforcing controlled substance laws, which intends to reschedule 7-OH as a Schedule I substance.

The details

Concentrated and synthetic 7-OH derivatives are sold as tablets, gummies, and drink mixes, while the substance occurs naturally in kratom leaves in very small amounts. Some laboratories have begun testing specifically for 7-OH and related substances.

Timeline

  1. 2023: 7-OH contributed to 65 overdose deaths in Pennsylvania.

  2. 2024: 7-OH contributed to 38 overdose deaths in Pennsylvania.

  3. 2025: 7-OH contributed to 33 overdose deaths in Pennsylvania.

  4. November 13, 2026: Planned DEA rescheduling of 7-OH and related substances takes effect.

  5. June 30, 2026: End of the poison control exposure recording period.

Big Picture

The planned DEA action extends the federal Schedule I framework used for synthetic opioids to kratom-derived 7-OH, a substance that sits in a regulatory gray area. Pennsylvania's warning shows how federal rescheduling can shift risk from regulated markets to illicit supply.

People who use 7-OH or kratom for pain management may face withdrawal symptoms and reduced access to these products once rescheduling takes effect. Those who do not identify as having a substance use disorder may find it harder to get appropriate care if they experience negative effects.

The takeaway

Anyone who uses 7-OH or kratom should be aware that federal rescheduling is scheduled for November 13, 2026, and should discuss withdrawal risks and alternatives with a health care provider before any change in access.

What happens next

The DEA's planned rescheduling of 7-OH, MGM-15, MGM-16, and tianeptine as Schedule I controlled substances is scheduled for November 13, 2026.

Further reading

Explore more on Substance Abuse to understand the risks tied to kratom-derived products.

Source note: This article includes information reported by Butlereagle.

Live Poll

Should the federal government ban kratom-derived products like 7-OH?